Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study
Journal Article
2011
Permanent link to this Item
Authors
Journal Title
BMC Research Notes
Link to Journal
Journal ISSN
Volume Title
Publisher
BioMed Central Ltd
Publisher
University of Cape Town
Faculty
Series
Abstract
BACKGROUND: Although otorrhea occurs commonly in HIV-infected infants, there are few data. We compared the incidence of otorrhea in infants receiving early vs deferred ART in the Children with HIV Early Antiretroviral (CHER) trial. Infants aged 6 to 12 weeks of age with confirmed HIV infection and a CD4 percentage greater than or equal to 25% were randomized to early or deferred ART at two sites in South Africa. Medical records from one study site were reviewed for otorrhea.FINDINGS:Data were reviewed from the start of the trial in July 2005 until 20 June 2007, when the Data Safety Monitoring Board recommended that randomization to the deferred arm should stop and that all infants in this arm be reviewed for commencing antiretroviral therapy. Infants entered the study at a median of 7.4 weeks of age. Eleven of 38 (29%) on deferred therapy and 7 of 75 (9%) in the early-therapy group developed otorrhea (risk ratio 3.1, 95% confidence interval (CI) 1.31-7.36; p = 0.01). CONCLUSIONS: Early initiation of antiretroviral therapy is associated with significantly less otorrhea than when a deferred strategy is followed.TRIAL REGISTRATION:NCT00102960. ClinicalTrials.Gov
Description
Keywords
Reference:
Hainline, C., Taliep, R., Sorour, G., Nachman, S., Rabie, H., Dobbels, E., ... & Cotton, M. F. (2011). Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. BMC research notes, 4(1), 448.